Dupilumab in Atopic Dermatitis – Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry
A distinct proportion of patients with atopic dermatitis and dupilumab treatment does not reach the primary endpoint of an eczema area severity index (EASI)-75 or investigator global assessment 0/1 after 16 weeks. Little is known about poor responders to dupilumab in real life scenarios. The study objective was to identify the percentage and characteristics of patients with insufficient treatment response to dupilumab based on "TREATgermany" registry data from dermatological routine care. Between 06/2016 and 12/2024, 476 patients matched the study criteria. In total, 4% of patients (n=19) were identified as dupilumab poor responders, i.e. reduction in EASI ≤40% at the 1st follow-up visit after 8 to 20 weeks and a consecutive 2nd follow-up visit up to 52 weeks of treatment. 44% (n=209) were classified as stable responders, i.e. decrease in EASI≥75% at both follow-up visits. Poor responders were significantly more often male, more frequently exhibited smoking, arterial hypertension and a higher body mass index. This TREATgermany data analysis demonstrates a proportion of 4% dupilumab poor responders within the first year of treatment. Male sex, smoking, arterial hypertension and increased body mass index were identified as potential risk factors. Further translational research is needed to confirm these clinical findings.
Authors
- Andreas Pinter (ORCID: https://orcid.org/0000-0002-1330-1502)
- Matthias Augustin (ORCID: https://orcid.org/0000-0002-4026-8728)
- Thomas Werfel (ORCID: https://orcid.org/0000-0001-6830-7672)
- Kathrin Meinhardt (ORCID: https://orcid.org/0009-0005-7826-5353)
- Stephan Traidl (ORCID: https://orcid.org/0000-0003-4806-599X)
- Sascha Fischer (ORCID: https://orcid.org/0009-0007-7191-8790)
- Michael Sticherling (ORCID: https://orcid.org/0000-0001-9396-3938)
- Christiane Handrick
- Tatjana Honstein (ORCID: https://orcid.org/0009-0001-2897-964X)
- Bernd Großmann
- Michael Schulz-Kiesow
- Sabine Anders
- Anne B. Bong
- Eva Moennig (ORCID: https://orcid.org/0009-0005-3676-4269)
- Jutta Ramaker‐Brunke
- Inken Harder (ORCID: https://orcid.org/0000-0002-3079-0440)
- Maren Stahl
- Sven Quist (ORCID: https://orcid.org/0000-0002-9548-7813)
- Annice Heratizadeh (ORCID: https://orcid.org/0000-0002-9231-9865)
- Jochen M. Schmitt (ORCID: https://orcid.org/0000-0003-0264-0960)
- Tilo Biedermann (ORCID: https://orcid.org/0000-0002-5352-5105)
- Nicole Adler
- Knut Schäkel (ORCID: https://orcid.org/0000-0001-6344-7799)
- Thomas Birkner (ORCID: https://orcid.org/0000-0002-1027-7295)
- Barbara Kind (ORCID: https://orcid.org/0009-0002-5254-6411)
- Stephan Weidinger (ORCID: https://orcid.org/0000-0003-3944-252X)
- Caroline G. Mann (ORCID: https://orcid.org/0000-0001-7044-2216)
- Hannah Gorriahn‐Maiterth
- Susanne Abraham (ORCID: https://orcid.org/0000-0001-7457-6481)
- S. Steinke
- Thomas Schaefer
- Felix Jacobs
- Joëlle Naim
- Katharina Lönnecke
- Beate Schwarz
- Carl-Philipp Buerkle
Institutions
- Jungheinrich (Germany) (DE)
- Universität Hamburg (DE)
- University Hospital Heidelberg (DE)
- Medizinische Hochschule Hannover (DE)
- Universitätsklinikum Erlangen (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital Schleswig-Holstein (DE)
- University Hospital Frankfurt (DE)
- Empolis (Germany) (DE)
- University Hospital Carl Gustav Carus (DE)
- Zentrum für Evidenzbasierte Gesundheitsversorgung (DE)
- Technical University of Munich (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- Acta Dermato Venereologica
- Published
- 2026-11-05
- DOI
- https://doi.org/10.2340/actadv.v106.adv-2026-0806
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00